Same Indication

Mirvetuximab Soravtansine vs Nivolumab

Mirvetuximab Soravtansine vs Nivolumab: Overview

This comparison examines the pharmacological differences between Mirvetuximab Soravtansine and Nivolumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days.

Chemical Properties

Type: Mirvetuximab Soravtansine β€” Antibody drug conjugate; Nivolumab β€” Antibody.